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ABSTRACT
Background Mitogen-activated protein (MAP) kinases
are key regulators of cytokine production, and are
therefore potential targets for treatment of rheumatoid
arthritis (RA).
Objective This two-part phase II study investigated the
efﬁcacy and safety of a once-daily 50 mg GLPG0259 (an
inhibitor of MAP kinase-activated protein kinase 5) dose
vs placebo (part A). An interim analysis after part A
would determine whether the dose-ﬁnding part (part B)
would be performed.
Methods In part A, eligible methotrexate (MTX)-
refractory patients with RA were randomised to receive
either a once-daily 50 mg dose of GLPG0259 or placebo,
in addition to a stable dose of MTX, for 12 weeks. The
primary efﬁcacy end point was the percentage of patients
achieving an American College of Rheumatology 20%
improvement (ACR20) response after 12 weeks.
Results The interim analysis showed no difference
between the percentage of subjects achieving the
primary efﬁcacy variable of ACR20 or the secondary
efﬁcacy variables (ACR50, ACR70 and Disease Activity
Score 28) at week 12 in the GLPG0259-treated (n=19)
and placebo-treated (n=11) groups. Owing to lack of
efﬁcacy, the study was terminated, and part B was not
initiated.
Conclusions This innovative study design quickly
provided conclusive results on the lack of efﬁcacy of
GLPG0259 in patients with RA.
INTRODUCTION
A key component of rheumatoid arthritis (RA) is
inﬂammation of the synovial membrane, accom-
panied by overexpression of several proinﬂamma-
tory cytokines.1–3
Mitogen-activated protein (MAP) kinases (eg,
p38 group) are key regulators of proinﬂammatory
cytokine and metalloproteinase production. MAP
kinase-activated protein kinase 5 (MAPKAPK5) has
recently been identiﬁed in synovial ﬁbroblasts of
patients with RA as a potential new target for
treatment.4 MAPKAPK5 is involved in a transduc-
tion pathway that leads to the secretion of cata-
bolic enzymes such as matrix metalloproteinase 1,
which can cause damage to bone and cartilage.
GLPG0259 is a ﬁrst-in-class, small-molecule
ATP-competitive inhibitor of MAPKAPK5. In cellular
assays, GLPG0259 reduced the release of several med-
iators of inﬂammation and bone degradation better
than or comparable to inhibitors of p38, janus acti-
vated kinase (JAK) and spleen tyrosine kinase (SYK).
GLPG0259 did not block phosphorylation of c-jun
NH(2)-terminal protein kinase (JNK), ERK and p38
MAP kinases, indicating inhibition of a kinase
downstream in cytokine-response pathways. In
addition, oral administration of GLPG0259 reduced
inﬂammation and bone destruction in the mouse
collagen-induced arthritis model.5
In phase I studies in healthy male subjects,
the maximum tolerated dose was established at
50 mg/day—a safe and well-tolerated dose when
co-administered with a single dose of 7.5 mg metho-
trexate (MTX).6 The pharmacokinetic proﬁle in
phase I studies supported a once-daily oral dosing
regimen.
The innovative trial design used here allows a
complete phase II programme to be carried out in
a single study.
METHODS
Patients
Between November 2010 and March 2011, patients
with active RA and an inadequate response to MTX
were treated for 12 weeks. See online supplementary
text for detailed inclusion and exclusion criteria.
Trial design
This was a phase II, randomised, double-blind,
placebo-controlled, multicentre trial (NCT01211249).
Part A (proof-of-concept) was designed to establish
efﬁcacy and safety of a once-daily dose of 50 mg
GLPG0259 compared with placebo, in addition to a
stable dose of MTX, over 12 weeks. It included
30 patients. A subsequent interim analysis of the
results from part Awould determine whether part B
(dose ﬁnding) would be initiated. Part B was designed
to increase the maximum number of patients to 200,
spread over four dose groups (high, middle, low,
placebo). This trial design limits the number of
patients exposed to high dose and placebo by includ-
ing in part B data from patients receiving these doses
in part A. More details on the study design are
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presented in ﬁgure 1 and the online supplementary text. The
study was conducted in accordance with the Declaration of
Helsinki and was consistent with the International Conference on
Harmonisation of Good Clinical Practice.
Efﬁcacy
The primary efﬁcacy variable was American College of
Rheumatology 20% improvement (ACR20) response at week 12.
The secondary efﬁcacy variables were: ACR20 response in each
treatment group at weeks 1, 2, 4 and 8; time to ACR20 response,
ACR50/ACR70 response, and change from baseline in Disease
Activity Score 28 (DAS28) using C-reactive protein (CRP) at
weeks 1, 2, 4, 8 and 12.
Safety
Safety data were summarised for the safety population (all
randomised patients who received one or more doses of
GLPG0259). Reported adverse events were coded using the
Medical Dictionary for Regulatory Activities 13.1 or higher (see
online supplementary text).
Pharmacokinetics
The pharmacokinetic analysis was descriptive, using plasma
concentrations of GLPG0259.
Statistical analysis
For the interim efﬁcacy analysis, a selection of efﬁcacy variables
were summarised for the intention-to-treat (ITT) population
(all randomised patients receiving ≥1 dose of GLPG0259 and
provided data for ≥1 post-baseline efﬁcacy assessment). The ACR
responses and DAS28 were derived using SAS V.9.1.3 or later.
RESULTS
Baseline demographics
Of the 69 patients screened, 31 met the inclusion criteria
and were randomised (2 : 1) to receive 50 mg/day GLPG0259
(n=20) or placebo (n=11). One patient (GLPG0259 group) dis-
continued the treatment because of low back pain which
occurred before treatment.
No clinically or biologically meaningful demographic or base-
line differences were found between the groups (table 1).
No patient had been treated with biological agents before
enrolment.
Thirty patients (19 in the GLPG0259 group; 11 in the
placebo group) received ≥1 dose of treatment and were included
in the safety population. All patients had ≥1 post-baseline efﬁ-
cacy assessment and were included in the ITT population.
Thus, safety and ITT populations were identical.
Of these 30 patients, 27 (87.1%) completed the study:
17 (85.0%) in the GLPG0259 group and 10 (90.9%) in the
placebo group; two withdrew consent (1 per group) and one dis-
continued for private reasons (GLPG0259 group). Four (20.0%)
patients in the GLPG0259 group required their dose to be split
(twice 25 mg/day); no patient required a dose reduction.
Primary efﬁcacy variable
Five patients (26.3%) in the GLPG0259 group and three
patients (27.3%) in the placebo group achieved an ACR20
response at week 12 (table 2). The ACR20 response rate in the
Figure 1 Design of the exploratory, randomised, double-blind, placebo-controlled, multicentre phase II trial. Duration and assessment schedule were
the same for part A and part B.
aIf the 50 mg/day dose was not tolerated by the patient, the investigator could decide to either split (twice-daily half-dose treatment) or reduce
(once-daily half-dose treatment) the daily dose.
bThe highest dose selected depends on the tolerability of the drug. If the highest dose selected for Part B was 50 mg/day, the 'High', 'Middle' and
'Low' dose groups received 50 mg, 25 mg and 12.5 mg of GLPG0259 respectively per day. If the highest dose selected for Part B was 25 mg/day,
the 'High', 'Middle' and 'Low' dose groups received 25 mg, 12.5 mg and 6 mg of GLPG0259, respectively, per day.
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placebo group was as expected and at a similar level as used in
the sample size calculation.
Secondary efﬁcacy variables
No patient achieved an ACR20 response at week 1. At weeks 2
and 4, the response rate in the placebo group was 27.3%; at
week 8, it increased to 45.5%, and stabilised back to 27.3% by
the end of the treatment period. The response rate in the
GLPG0259 group increased from 10.5% at weeks 2 and 4 to
21.1% at week 8 and 26.3% by the end of the treatment period
(table 2).
The median time to ACR20 response among ACR20 res-
ponders was 41.0 days (GLPG0259 group) and 20.5 days
(placebo group).
One (5.3%) patient in the GLPG0259 group and two (18.2%)
in the placebo group achieved an ACR50 response at week 8.
No other patients achieved an ACR50 response at any other
time point. No patient achieved an ACR70 response at any time.
In the GLPG0259 group, the mean decrease from baseline
DAS28 (CRP) did not exceed 0.6 across the visits, while in the
placebo group it was just over 1.1 at both weeks 8 and 12.
Mean changes from baseline CRP showed a consistently
larger decrease in the GLPG0259 group over the 12-week treat-
ment period compared with the placebo group (table 2).
Safety
GLPG0259 at 50 mg/day over 12 weeks was considered safe and
well-tolerated, with observed treatment-emergent adverse
events (TEAEs) consistent with the expected safety proﬁle (see
online supplementary text and online supplementary table S1).
No serious TEAEs or TEAEs leading to study discontinuation
were reported.
Pharmacokinetics
Plasma GLPG0259 concentrations were well within the range
observed in healthy volunteers at the same dose level (see online
supplementary text and online supplementary ﬁgure S1).
DISCUSSION
The interim analysis of the primary efﬁcacy variable (ACR20)
showed that 50 mg GLPG0259 orally administered once daily is
not superior to placebo. The innovative phase II study design
allowed early independent analysis and evaluation of
proof-of-concept data, eventually resulting in discontinuation of
the study. All secondary efﬁcacy variables showed results con-
sistent with those of the primary efﬁcacy end point. This study
also conﬁrmed the results of previous phase I studies6 indicating
that GLPG0259 is well tolerated at a once-daily 50 mg dose.
The lack of efﬁcacy may be explained by the following.
(1) The impact of MAPKAPK5 inhibition on the pathogenesis of
RA has not yet been demonstrated in patients. (2) Although
plasma exposures in patients were similar to exposures to active
dosages in animal models, data indicating that the enzyme
pathway is signiﬁcantly inhibited at current plasma concentra-
tions in the target tissues of patients are lacking. However,
reduced CRP levels suggest some effectiveness of the adminis-
tered dose. Higher dosages were not tested because of safety con-
siderations. (3) This particular inﬂammation pathway is a
complex pathway, and multiple modalities are involved in acti-
vation and inhibition. Blocking one involved kinase may lead to
compensatory effects in the others. The number of failed studies
with p38 MAPK inhibitors lends some weight to this.
There is a need for oral drugs that are effective in treating
RA. Several drugs in development have targeted recently identi-
ﬁed pathways7 8; however, not all have shown efﬁcacy.9 Trial
designs such as ours will help shorten the development process.
Table 2 ACR20 response rates and CRP levels during the 12-week study period
ACR20 responders, n (%) CRP (mg/l)
GLPG0259 50 mg/day (n=19) Placebo (n=11) GLPG0259 50 mg/day (n=19) Placebo (n=11)
Baseline 36.5±8.1 34.0±9.1
Week 1 0 [NA] 0 [NA] 37.9±6.8 39.1±10.2
Week 2 2 (10.5) [1.3 to 33.1] 3 (27.3) [6.0 to 61.0] 23.5±3.3 37.2±11.3
Week 4 2 (10.5) [1.3 to 33.1] 3 (27.3) [6.0 to 61.0] 25.4±4.7 50.1±15.5
Week 8 4 (21.1) [6.1 to 45.6] 5 (45.5) [16.7 to 76.6] 29.1±4.3 40.8±11.2
Week 12 5 (26.3) [9.1 to 51.2] 3 (27.3) [6.0 to 61.0] 27.0±4.5 42.5±12.4
Square brackets contain 95% CIs. CRP values presented as mean±SEM.
Last observation carried forward was applied to each component variable of the ACR20 response calculation. Percentages were calculated based on the number of patients in
the intention-to-treat population in each treatment group.
ACR20, American College of Rheumatology 20% improvement in disease activity; CRP, C-reactive protein; NA, not applicable.
Table 1 Baseline characteristics and disease status (safety/ITT
population)
GLPG0259 (n=19) Placebo (n=11)
Baseline characteristics
Age (years) 50 (27, 69) 52 (30, 64)
Sex (male/female) 5/14 4/7
Race (Caucasian) 19 11
Height (cm) 169 (159, 180) 169 (158, 194)
Weight (kg) 74 (47, 98) 75 (49, 95)
BMI (kg/m2) 25.9 (16.9, 38.3) 26.6 (17.8, 35.8)
Disease status at screening
RF positive 73.7% 90.9%
Anti-CCP positive 78.9% 81.8%
RF and anti-CCP positive 73.7% 81.8%
Serum CRP (mg/l) 52 (18, 122) 41 (16, 107)
Disease status at baseline
Serum CRP (mg/l) 37 (2, 129) 34 (5, 97)
SJC66 12 (6, 19) 15 (5, 33)
TJC68 20 (7, 35) 23 (0, 35)
DAS28 (CRP) 5.83 (4.98, 7.27) 6.12 (5.17, 7.20)
Use of oral steroids 57.9% 63.6%
Current dose of MTX (mg/week) 10.66 (7.5–20) 11.36 (7.5–20)
Age expressed as median (range); height, weight, BMI, serum CRP, SJC66, TJC68,
DAS28 (CRP) and current dose of MTX expressed as mean (range).
BMI, body mass index; CCP, cyclic citrullinated peptide; CRP, C-reactive protein;
DAS, Disease Activity Score; ITT, intention-to-treat; MTX, methotrexate; RF,
rheumatoid factor; SJC, swollen joint count; TJC, tender joint count.
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Our innovative trial design makes a complete phase II pro-
gramme possible in a single study. The interim analysis pro-
vided results very quickly. Hence, the study could be
terminated more quickly, thus limiting the number of subjects
exposed to a drug in early development or to placebo. In
general, small numbers of patients can be used in well-deﬁned
disease areas, where historical placebo response data can valid-
ate any effects observed. If the experimental medication does
not show a predeﬁned substantial increment in effect, as
benchmarked by active drugs in the market, a clear cut answer
can be obtained. To ensure that a novel compound is not
unduly discontinued, advice from an external expert panel that
has reviewed all available data is essential.
In summary, this phase II study of oral GLPG0259 was the
ﬁrst to investigate the efﬁcacy of small-molecule inhibition of
MAPKAPK5, a new target for the treatment of RA. Further
investigations on drugs aimed at potential targets for the treat-
ment of RA are warranted.
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